Pre-transplant testosterone and outcome of men after allogeneic stem cell transplantation.
Journal
Haematologica
ISSN: 1592-8721
Titre abrégé: Haematologica
Pays: Italy
ID NLM: 0417435
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
23
02
2019
accepted:
10
07
2019
pubmed:
13
7
2019
medline:
28
4
2021
entrez:
13
7
2019
Statut:
ppublish
Résumé
Testosterone is an important determinant of endothelial function and vascular health in men. As both factors play a role in mortality after allogeneic stem cell transplantation (alloSCT), we retrospectively evaluated the impact of pre-transplant testosterone levels on outcome in male patients undergoing alloSCT. In the discovery cohort (n=346), an impact on outcome was observed only in the subgroup of patients allografted for acute myeloid leukemia (AML) (n=176, hereafter termed 'training cohort'). In the training cohort, lower pre-transplant testosterone levels were significantly associated with shorter overall survival (OS) [hazard ratio (HR) for a decrease of 100 ng/dL: 1.11,
Identifiants
pubmed: 31296579
pii: haematol.2019.220293
doi: 10.3324/haematol.2019.220293
pmc: PMC7193480
doi:
Substances chimiques
Testosterone
3XMK78S47O
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1454-1464Informations de copyright
Copyright© 2020 Ferrata Storti Foundation.
Références
Cancer Lett. 1994 Jan 30;76(2-3):81-6
pubmed: 8149350
PLoS One. 2016 Sep 21;11(9):e0162480
pubmed: 27655114
Hum Reprod Update. 2001 Jul-Aug;7(4):363-9
pubmed: 11476348
Eur Heart J. 2016 Dec 21;37(48):3569-3575
pubmed: 26637832
Leukemia. 2014 Oct;28(10):1978-1987
pubmed: 24637335
Arterioscler Thromb Vasc Biol. 2012 Feb;32(2):481-6
pubmed: 22095984
Biol Blood Marrow Transplant. 2009 Dec;15(12):1628-33
pubmed: 19896087
Cancer. 1986 Aug 1;58(3):617-23
pubmed: 3524789
Blood. 2011 Aug 11;118(6):1685-92
pubmed: 21636856
Eur Cytokine Netw. 2012 Oct-Dec;23(4):140-53
pubmed: 23328436
Carcinogenesis. 2013 Mar;34(3):667-77
pubmed: 23239744
Ann Med. 2008;40(3):215-22
pubmed: 18382887
Cancer. 2009 Oct 15;115(20):4715-26
pubmed: 19642176
JAMA. 2017 Feb 21;317(7):708-716
pubmed: 28241355
Horm Mol Biol Clin Investig. 2014 May;18(2):89-103
pubmed: 25390005
Bone Marrow Transplant. 2017 Mar;52(3):431-437
pubmed: 27941768
Biol Blood Marrow Transplant. 2016 Sep;22(9):1573-1581
pubmed: 27246373
J Clin Endocrinol Metab. 1992 Apr;74(4):939-42
pubmed: 1548361
Hum Reprod. 2003 Jul;18(7):1410-6
pubmed: 12832364
Br J Haematol. 2009 Jan;144(1):53-68
pubmed: 19016730
Blood. 2005 Oct 15;106(8):2912-9
pubmed: 15994282
Lancet Oncol. 2012 Oct;13(10):1035-44
pubmed: 22959335
J Transplant. 2014;2014:404096
pubmed: 25374676
Hypertens Res. 2007 Nov;30(11):1029-34
pubmed: 18250551
Arch Intern Med. 2006 Aug 14-28;166(15):1660-5
pubmed: 16908801
Front Immunol. 2018 Nov 13;9:2601
pubmed: 30483263
J Clin Endocrinol Metab. 2011 Oct;96(10):3007-19
pubmed: 21816776
Cancer. 1980 Apr 1;45(7):1540-8
pubmed: 6929214
Bone Marrow Transplant. 2000 Nov;26(10):1089-95
pubmed: 11108308
Haematologica. 2019 Apr;104(4):827-834
pubmed: 30514796
Atherosclerosis. 2016 May;248:245-51
pubmed: 26972631
Ther Adv Drug Saf. 2014 Oct;5(5):190-200
pubmed: 25360240
Eur Heart J. 2010 Jun;31(12):1494-501
pubmed: 20164245
N Engl J Med. 2013 Aug 8;369(6):529-39
pubmed: 23924003
Biol Blood Marrow Transplant. 2008 Jan;14(1 Suppl 1):23-32
pubmed: 18162218
Blood. 2007 Nov 1;110(9):3463-71
pubmed: 17664354
Clin Trials. 2014 Jun;11(3):362-375
pubmed: 24686158
J Clin Oncol. 2017 Feb;35(4):387-393
pubmed: 28129526